filler About Prescribing Information Dosing & Administration Safety Information Coverage & Assistance Clinical Resources Samples Request

The FDA has confirmed there are no generic substitutes for BiDil.15

Please scroll down to view Indication and Important Safety Information or click here.

Welcome to the BiDil Clinical Resource page. We understand that Healthcare Providers need to make daily decisions based on solid clinical data. This page has been organized to provide helpful information about BiDil and the benefits it provides for African American patients with heart failure. You are welcome to view each icon or download it for future use.


Medical Affairs
If you have any questions regarding the use of BiDil please contact Medical Affairs at 888-692-4345.

BiDil's Clinical Story
This slide presentation provides a comprehensive view of heart failure in African-Americans, A-HeFT and the use of BiDil.

Clinical Pharmacokinetics
Lack of Bioequivalence between ISDN and Hydralazine and FDC of ISDN/Hydralazine

There are No Generic Equivalents for BiDil - The Evidence
This slide presentation highlights the differences between BiDil vs. ISDN and hydralazine.

African-American Heart Failure Trial
Click on this icon to view and download this landmark publication that highlights the benefits of BiDil for the treatment of heart failure in African Americans.

FDA letter confirming no generic equivalents to BiDil
Click on this icon to view or download the FDA letter that states there are currently no generic equivalents to BiDil.

Important information about BiDil®
(isosorbide dinitrate/hydralazine hydrochloride):

BiDil is indicated for the treatment of heart failure as an adjunct to standard therapy in self-identified black patients to improve survival, to prolong time to hospitalization for heart failure, and to improve patient-reported functional status. There is little experience in patients with NYHA class IV heart failure. Most patients in the clinical trial supporting effectiveness (A-HeFT) received a loop diuretic, an angiotensin converting enzyme inhibitor or an angiotensin II receptor blocker, and a beta blocker, and many also received a cardiac glycoside or an aldosterone antagonist.

BiDil is contraindicated in patients who are allergic to organic nitrates.

Augmentation of the vasodilatory effects of isosorbide dinitrate by phosphodiesterase inhibitors such as sildenafil, vardenafil, or tadalafil could result in severe hypotension.  The time course and dose dependence of this interaction have not been studied. Reasonable supportive care should consist of those measures used to treat a nitrate overdose with elevation of the extremities and central volume expansion.

Treatment with hydralazine hydrochloride may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis.  If systemic lupus erythematosus-like symptoms occur in patients treated with BiDil, discontinuation of BiDil should be considered only after a thorough benefit-to-risk assessment.  Symptoms and signs of systemic lupus erythematosus usually regress when hydralazine hydrochloride is discontinued but residua have been detected many years later.  Long-term treatment with steroids may be necessary.

Symptomatic hypotension, particularly with upright posture, may occur with even small doses of BiDil.  BiDil should be used with caution in patients who may be volume depleted or who are already hypotensive.

Hydralazine hydrochloride can cause tachycardia potentially leading to myocardial ischemia and angina attacks.  Careful clinical and hemodynamic monitoring is recommended when BiDil is administered to patients with acute myocardial infarction to avoid the hazards of hypotension and tachycardia.

Hydralazine hydrochloride has been associated with peripheral neuritis, evidenced by paresthesia, numbness, and tingling, which may be related to an antipyridoxine effect.  Pyridoxine should be added to BiDil therapy if such symptoms develop.

Isosorbide dinitrate therapy may aggravate angina associated with hypertrophic cardiomyopathy.

Headache and dizziness were the most frequent adverse events occurring at an incidence greater than 2% in clinical studies compared to placebo.  Others included chest pain, asthenia, nausea, bronchitis, hypotension, sinusitis, ventricular tachycardia, palpitations, hyperglycemia, rhinitis, paresthesia, vomiting, amblyopia, hyperlipidemia, and tachycardia.

The full Prescribing Information for BiDil is available here.


Copyright © 2014 Arbor™ Pharmaceuticals, LLC       All Rights Reserved.